Status:
COMPLETED
A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the drug levels of BMS-986166 in healthy male participants.
Eligibility Criteria
Inclusion
- Healthy male participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory determinations
- Body mass index between 18.0 to 33.0 kg/m2 (inclusive)
Exclusion
- Any significant acute or chronic medical illness
- Current or recent history of constipation or irregular bowel movement (less than 1 bowel movement per day within the last 1 week)
- History of allergy (such as rash, hives, breathing difficulties) to any medications, either prescription or nonprescription
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
June 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2022
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT05409157
Start Date
June 17 2022
End Date
October 15 2022
Last Update
March 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Madison, Wisconsin, United States, 53704-2526